News
Public · Published
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST heart pump program. The device is a miniature heart pump designed to treat acute myocardial infarction cardiogenic shock, a life-threatening emergency when the heart cannot pump enough blood.
Published:
Updated:
What happened
Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST heart pump program. The device is a miniature heart pump designed to treat acute myocardial infarction cardiogenic shock, a life-threatening emergency when the heart cannot pump enough blood.
Confirmed
Global impact / market context
Splitting development costs lets Boston Scientific spend less of its own cash on the VITALYST heart pump while keeping a partner with a stake in its success. For Blackstone, the deal is a bet that payments tied to the product's progress can pay off if it reaches patients.
Analyst inference
This is the first time the two firms have co-funded a Boston Scientific product, which suggests device makers may increasingly share the cost and risk of bringing new heart pumps to market. That can change how investors view research spending, cash needs and future revenue from such devices.
Analyst inference
What to watch
- The VITALYST system is intended to increase cardiac output, which means the amount of blood the heart pumps, and improve blood flow to the brain and other vital organs in critically ill patients. Confirmed
- The companies aim to improve efficacy, safety and ease of use for physicians treating cardiogenic shock, so watch for development updates on whether the device meets those stated goals. Proposed
- Because the firms will share development funding, watch how Boston Scientific's research spending and cash position change, and whether the arrangement includes milestone payments to Blackstone. Analyst inference
Evidence
- Original source link unavailable